中电信(00728.HK)拟发行最多120.93亿股A股於上交所主板上市
中国电信(00728.HK)拟申请发行A股并在上交所主板上市,发行A股数量不超过120.93亿股,不超过A股发行後、超额配售选择权行使前已发行总股本的13%。
在符合法规及监管要求下,中电信可在本次A股发行时实施战略配售。在是次A股发行完成及倘超额配售权获悉数行使,H股股东持股比例料将由17.15%下降至14.63%。
公司表示,申请A股上市将把握数字化发展机遇,完善公司治理,拓宽融资渠道,加快改革发展,推动战略落地,实现高质量发展。决议案已於今日(9日)经董事会审议通过,将提请股东会议审议批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.